APA (7th ed.) Citation

A, H., MA, C. R., E, P., C, G., S, H., F, A., & C, N. (2022). Efficacy of pembrolizumab in a patient with xeroderma pigmentosum variant and advanced cutaneous squamous-cell carcinoma. Acta oncologica (Stockholm, Sweden), 61(9), 1140. https://doi.org/10.1080/0284186X.2022.2109425

Chicago Style (17th ed.) Citation

A, Hennemann, Collonge Rame MA, Puzenat E, Ged C, Harbon S, Aubin F, and Nardin C. "Efficacy of Pembrolizumab in a Patient with Xeroderma Pigmentosum Variant and Advanced Cutaneous Squamous-cell Carcinoma." Acta Oncologica (Stockholm, Sweden) 61, no. 9 (2022): 1140. https://doi.org/10.1080/0284186X.2022.2109425.

MLA (9th ed.) Citation

A, Hennemann, et al. "Efficacy of Pembrolizumab in a Patient with Xeroderma Pigmentosum Variant and Advanced Cutaneous Squamous-cell Carcinoma." Acta Oncologica (Stockholm, Sweden), vol. 61, no. 9, 2022, p. 1140, https://doi.org/10.1080/0284186X.2022.2109425.